A sequentially targeted and pathology-responsive nanoplatform for synergistic treatment of dry eye disease via concurrent anti-inflammation and mitochondrial ROS scavenging - PubMed
3 hours ago
- #nanoplatform
- #sequential targeting
- #dry eye disease
- A nanoplatform named CFMPDA is developed for synergistic treatment of dry eye disease (DED) by targeting inflammation and oxidative stress.
- CFMPDA uses sequential targeting: CCL2 antibodies enable binding to inflamed corneas, followed by mitochondrial targeting to deliver anti-inflammatory and antioxidant therapy.
- The nanoplatform encapsulates anti-inflammatory Fuziline in mesoporous polydopamine (MPDA) for scavenging reactive oxygen species (ROS).
- In a DED mouse model, CFMPDA outperformed Fluorometholone, suppressing inflammatory markers and quenching oxidative stress, leading to tissue repair and functional recovery.